Click Therapeutics kicks off digital therapy remote trial for migraine
Pharmaceutical Technology
APRIL 26, 2023
in December 2022, the digital therapy, called CT-132, secured a Breakthrough Device designation from the US Food and Drug Administration (FDA) as an adjunctive preventive treatment for episodic migraine in patients above the age of 18 years. Its use is especially applicable in mental health and neurology.
Let's personalize your content